About Shield Therapeutics
Shield Therapeutics is a company based in Gateshead (United Kingdom) founded in 2008. Shield Therapeutics has raised $58.86 million across 4 funding rounds from investors including AOP Health and Inventages. The company has 63 employees. Shield Therapeutics offers products and services including ACCRUFeR®. Shield Therapeutics operates in a competitive market with competitors including Freeline, Keros Therapeutics, Jasper Therapeutics, Disc Medicine and Interius Biotherapeutics, among others.
- Headquarter Gateshead, United Kingdom
- Employees 63
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website shieldtherapeutics.com
- Social LinkedIn X Facebook
- Legal Name Shield Therapeutics Plc
- Annual Revenue$50.78 M (USD)49.75as on Dec 31, 2025
- Net Profit-$18.04 M (USD)37.02as on Dec 31, 2025
- EBITDA-$9.17 M (USD)59.63as on Dec 31, 2025
- Total Equity Funding$58.86M (USD)
in 4 rounds
- Latest Funding Round$6.1M (USD), Post-IPO
Sep 2023
- InvestorsAOP Health
& 1 more
- Employee Count63
Products & Services of Shield Therapeutics
Shield Therapeutics offers a comprehensive portfolio of products and services, including ACCRUFeR®.
Stable oral treatment for iron deficiency in adults.
Funding Insights of Shield Therapeutics
Shield Therapeutics has successfully raised a total of $58.86M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6.1 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $58.86M
- Total Rounds 4
- Last Round Post-IPO — $6.1M
- First Round $11.79M
(Jun 2011)
- Investors Count 2
All 4 funding rounds of Shield Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $6.1M | Post-IPO | – | – | – |
| Jun 2022 | $10M | Post-IPO | – | – | |
| Feb 2016 | $47.07M | Series B | – | – | – |
| Jun 2011 | $11.79M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Shield Therapeutics
Shield Therapeutics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include AOP Health and Inventages.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | inventages.com | - | |
Develops innovative technologies for treatments targeting rare diseases. | 1996 | aop-health.com | Vienna, Austria |
Investor details for Shield Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Shield Therapeutics
1 people are tracked at Shield Therapeutics (1 in leadership); the tracked headcount is 63.
| Name | Role | Group |
|---|---|---|
Greg Madison | CEO | Leadership |
Complete people profiles for Shield Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Shield Therapeutics
Shield Therapeutics is a publicly listed company on the LSE with ticker symbol STX in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Feb 2016
- Listed onLSE: STX
- Listed entityShield Therapeutics Plc
- Exchange sectorHealth technology
- ISINGB00BYV81293
- Share price5.30 GBX (+0.95% on the day) · 2026-10-09
- Market capitalisation56,930,352.00 GBX
- EPS (diluted, trailing year)-0.01 GBX
- Volume (last session)581,508
Financials of Shield Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 37.7M GBP | -13.4M GBP | -6.8M GBP |
| 2024 | 25.2M GBP | -21.3M GBP | -16.9M GBP |
| 2023 | 10.5M GBP | -26.8M GBP | -27.9M GBP |
| 2022 | 4.5M GBP | -40.4M GBP | -24.1M GBP |
| 2021 | 1.5M GBP | -19.7M GBP | -18.2M GBP |
Detailed financial statements for Shield Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Shield Therapeutics
4 dated milestones of Shield Therapeutics across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Shield Therapeutics is founded.
- Funding First funding round of $11.8M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $6.1M.
Competitors of Shield Therapeutics
Shield Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Freeline, Keros Therapeutics, Jasper Therapeutics, Disc Medicine and Interius Biotherapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| kerostx.com | 2016 | Lexington, United States | $90M | 136 | Small molecules are developed to treat hematologic and musculoskeletal disorders. | |
| jaspertx.com | 1999 | Redwood, United States | $84.1M | – | Developer of therapeutics for chronic diseases by targeting mast cells and stem cells | |
| discmedicine.com | 2017 | Cambridge, United States | $140M | 23 | Developer of therapeutics for the treatment of hematologic diseases | |
| interiusbio.com | 2020 | Philadelphia, United States | $129.03M | 25 | Developer of gene therapies for treating multiple diseases | |
| chinabiologic.com | 2002 | Guiyang, China | $300M | 1 | Human plasma-based biopharmaceutical products are developed and commercialized. | |
| cellphire.com | 2006 | Rockville, United States | $25.3M | 62 | Platelet-based therapeutics for hemostasis and regenerative medicine are developed. | |
| renibus.com | 2013 | Southlake, United States | $153.52M | – | Therapeutics for kidney diseases are developed by Renibus Therapeutics. |
Detailed competitors of Shield Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Shield Therapeutics
The website of Shield Therapeutics (shieldtherapeutics.com) receives about 3.2K visits a month.
- Monthly visits3.2K
▲ 30.5% vs previous month
Websites whose visitors overlap most with Shield Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| techmet.com | 100% | 8.5K | #2,757,436 | View details | |
| nwf.co.uk | 99% | 4.1K | #4,337,378 | View details | |
| vision-blue.com | 99% | 2.2K | #7,764,386 | View details | |
| venterra-group.com | 97% | 3.5K | #4,980,594 | View details | |
| uemtrust.co.uk | 97% | 1.5K | #12,398,225 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Shield Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Shield Therapeutics
Complete news archive for Shield Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Shield Therapeutics
10 companies that operate in the same segment as Shield Therapeutics (Hematology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small activating RNA therapeutics are developed to restore gene function. | 2008 | London, England, United Kingdom | USD 460.41 M | USD 23.07 M | 37 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 442 M | – | 66 | |
Developer of therapeutics for the treatment of hematologic diseases | 2017 | Cambridge, Massachusetts, United States | USD 140 M | – | 84 | |
Gene therapy platform is developed for chronic disease treatments. | 2015 | Stevenage, Hertfordshire, United Kingdom | USD 273.69 M | USD 435.87 K | 152 | |
Novel anticoagulants for thrombosis treatment are developed. | 2019 | Cambridge, Massachusetts, United States | USD 250 M | – | 14 | |
Developer of therapies for treating hemochromatosis & beta thalassemia | 1989 | San Diego, California, United States | – | USD 75.72 M | 71 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Hematology products and solutions are provided for medical applications. | 1971 | Braintree, Massachusetts, United States | – | USD 1.33 B | 3,020 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Shield Therapeutics
Shield Therapeutics was founded in 2008 and raised its 1st funding round 3 years after it was founded.
Shield Therapeutics is headquartered in Gateshead, United Kingdom. It is registered at Gateshead, England, United Kingdom.
Greg Madison is the current CEO of Shield Therapeutics.
Shield Therapeutics is a funded company, having raised a total of $58.86M across 4 funding rounds to date. The company's 1st funding round was a Series A of $11.79M, raised on Jun 2011.
Shield Therapeutics has 63 employees.
Annual revenue of Shield Therapeutics is $50.78M as on Dec 31, 2025.
Shield Therapeutics was founded in 2008 and is headquartered in Gateshead, United Kingdom. Pharmaceuticals are developed by the company within the healthcare sector, focusing on treatments for iron deficiency anemia and hyperphosphatemia. Operations center on oral and intravenous therapies, including the lead product Feraccru for adult iron deficiency, an iron-based phosphate binder PT20 for chronic kidney disease patients, hypo-allergenic IV iron PT30, and a generic iron sucrose PT40.
Shield Therapeutics's top competitors include Keros Therapeutics, Disc Medicine and Freeline.
Shield Therapeutics offers ACCRUFeR®.
Yes, Shield Therapeutics is publicly traded on LSE under the ticker symbol STX.
Shield Therapeutics has 2 investors. Key investors include AOP Health, and Inventages.
Shield Therapeutics operates through Shield Therapeutics Plc.